JAK/STAT signal transduction: Regulators and implication in hematological malignancies

Biochemical Pharmacology

Volumn 71, Issue 6, 2006, Pages 713-721

  Valentino, Lyne ^a   Pierre, Josiane ^a  

^a INSERM   (France)

Author keywords

JAK STAT pathway; Oncogenesis; Regulation of STAT activity; Signal transduction

Indexed keywords

CD45 ANTIGEN; CYTOKINE; CYTOKINE RECEPTOR; ESTERASE; GROWTH FACTOR; HORMONE; HYBRID PROTEIN; JANUS KINASE; JANUS KINASE 2; PROTEIN; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE SHP; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; TRANSCRIPTION FACTOR; TYROSINE PHOSPHATASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ATTENUATION; CANCER CELL; CARCINOGENESIS; DEREGULATION; DIMERIZATION; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TRANSLOCATION; HEMATOLOGIC MALIGNANCY; HUMAN; METHYLATION; MYELOPROLIFERATIVE DISORDER; NONHUMAN; ONCOGENE; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

EID: 32144453842     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.12.017     Document Type: Note

References (103)

1. W.J. Leonard, and J.J. O'Shea Jaks and STATs: biological implications Annu Rev Immunol 16 1998 293 322
2. P. Saharinen, K. Takaluoma, and O. Silvennoinen Regulation of the Jak2 tyrosine kinase by its pseudokinase domain Mol Cell Biol 20 2000 3387 3395
3. J.A. Girault, G. Labesse, J.P. Mornon, and I. Callebaut Janus kinases and focal adhesion kinases play in the 4.1 band: a superfamily of band 4.1 domains important for cell structure and signal transduction Mol Med 4 1998 751 769
4. D. Kampa, and J. Burnside Computational and functional analysis of the putative SH2 domain in Janus Kinases Biochem Biophys Res Commun 278 2000 175 182
5. V. Lacronique, A. Boureux, V.D. Valle, H. Poirel, C.T. Quang, and M. Mauchauffe A TEL-JAK2 fusion protein with constitutive kinase activity in human leukaemia Science 278 1997 1309 1312
6. P. Peeters, S.D. Raynaud, J. Cools, I. Wlodarska, J. Grosgeorge, and P. Philip Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia Blood 90 1997 2535 2540
7. F. Griesinger, H. Hennig, F. Hillmer, M. Podleschny, R. Steffens, and A. Pies A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia Genes Chromosomes Cancer 44 2005 329 333
8. T.R. Golub, A. Goga, G.F. Barker, D.E. Afar, J. McLaughlin, and S.K. Bohlander Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia Mol Cell Biol 16 1996 4107 4116
9. J.R. McWhirter, D.L. Galasso, and J.Y. Wang A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins Mol Cell Biol 13 1993 7587 7595
10. A. Reiter, C. Walz, A. Watmore, C. Schoch, I. Blau, and B. Schlegelberger The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2 Cancer Res 65 2005 2662 2667
11. M. Bousquet, C. Quelen, V. De Mas, E. Duchayne, B. Roquefeuil, and G. Delsol The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene Oncogene 24 2005 7248 7252
12. E.J. Baxter, L.M. Scott, P.J. Campbell, C. East, N. Fourouclas, and S. Swanton Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 365 2005 1054 1061
13. C. James, V. Ugo, J.P. Le Couedic, J. Staerk, F. Delhommeau, and C. Lacout A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 2005 1144 1148
14. D.P. Steensma, G.W. Dewald, T.L. Lasho, H.L. Powell, R.F. McClure, and R.L. Levine The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and the myelodysplastic syndrome Blood 106 2005 1207 1209
15. R. Kralovics, F. Passamonti, A.S. Buser, S.S. Teo, R. Tiedt, and J.R. Passweg A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 352 2005 1779 1790
16. R.L. Levine, M. Wadleigh, J. Cools, B.L. Ebert, G. Wernig, and B.J. Huntly Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 7 2005 387 397
17. R. Zhao, S. Xing, Z. Li, X. Fu, Q. Li, and S.B. Krantz Identification of an acquired JAK2 mutation in polycythemia vera J Biol Chem 280 2005 22788 22792
18. S. Joos, M. Granzow, H. Holtgreve-Grez, R. Siebert, L. Harder, and J.I. Martin-Subero Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2 Int J Cancer 103 2003 489 495
19. J.E. Darnell Jr. STATs and gene regulation Science 277 1997 1630 1635
20. A.E. Horvai, L. Xu, E. Korzus, G. Brard, D. Kalafus, and T.M. Mullen Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300 Proc Natl Acad Sci USA 94 1997 1074 1079
21. J.J. Zhang, U. Vinkemeier, W. Gu, D. Chakravarti, C.M. Horvath, and J.E. Darnell Jr. Two contact regions between Stat1 and CBP/p300 in interferon gamma signaling Proc Natl Acad Sci USA 93 1996 15092 15096
22. T. Decker, and P. Kovarik Serine phosphorylation of STATs Oncogene 19 2000 2628 2637
23. C.M. Litterst, and E. Pfitzner An LXXLL motif in the transactivation domain of STAT6 mediates recruitment of NCoA-1/SRC-1 J Biol Chem 277 2002 36052 36060
24. T. Valineva, J. Yang, R. Palovuori, and O. Silvennoinen The transcriptional co-activator protein p100 recruits histone acetyltransferase activity to STAT6 and mediates interaction between the CREB-binding protein and STAT6 J Biol Chem 280 2005 14989 14996
25. J. Bromberg Stat proteins and oncogenesis J Clin Invest 109 2002 1139 1142
26. R. Catlett-Falcone, T.H. Landowski, M.M. Oshiro, J. Turkson, A. Levitzki, and R. Savino Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells Immunity 10 1999 105 115
27. D.L. Silver, H. Naora, J. Liu, W. Cheng, and D.J. Montell Activated signal transducer and activator of transcription (STAT) 3 localization in focal adhesions and function in ovarian cancer cell motility Cancer Res 64 2004 3550 3558
28. A. Stephanou, and D.S. Latchman STAT-1: a novel regulator of apoptosis Int J Exp Pathol 84 2003 239 244
29. D. Banville, R. Stocco, and S.H. Shen Human protein tyrosine phosphatase 1C (PTPN6) gene structure: alternate promoter usage and exon skipping generate multiple transcripts Genomics 27 1995 165 173
30. J.G. Herman, and S.B. Baylin Gene silencing in cancer in association with promoter hypermethylation N Engl J Med 349 2003 2042 2054
31. P.A. Jones, and P.W. Laird Cancer epigenetics comes of age Nat Genet 21 1999 163 167
32. T. Oka, M. Ouchida, M. Koyama, Y. Ogama, S. Takada, and Y. Nakatani Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas Cancer Res 62 2002 6390 6394
33. Q. Zhang, H.Y. Wang, M. Marzec, P.N. Raghunath, T. Nagasawa, and M.A. Wasik STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes Proc Natl Acad Sci USA 102 2005 6948 6953
34. C.S. Chim, T.K. Fung, W.C. Cheung, R. Liang, and Y.L. Kwong SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway Blood 103 2004 4630 4635
35. M.F. Johan, D.T. Bowen, M.E. Frew, A.C. Goodeve, and J.T. Reilly Aberrant methylation of the negative regulators RASSFIA SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia Br J Haematol 129 2005 60 65
36. P. Fischer, U. Lehmann, R.M. Sobota, J. Schmitz, C. Niemand, and S. Linnemann The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling Biochem J 378 2004 449 460
37. J.M. Johannes, E.R. Garcia, G.A. De Vaan, and R.S. Weening Noonan's syndrome in association with acute leukaemia Pediatr Hematol Oncol 12 1995 571 575
38. T. Araki, M.G. Mohi, F.A. Ismat, R.T. Bronson, I.R. Williams, and J.L. Kutok Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation Nat Med 10 2004 849 857
39. M. Tartaglia, C.M. Niemeyer, A. Fragale, X. Song, J. Buechner, and A. Jung Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia Nat Genet 34 2003 148 150
40. I.S. Trowbridge, and M.L. Thomas CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development Annu Rev Immunol 12 1994 85 116
41. M.L. Hermiston, Z. Xu, and A. Weiss CD45: a critical regulator of signaling thresholds in immune cells Annu Rev Immunol 21 2003 107 137
42. J.V. Frangioni, P.H. Beahm, V. Shifrin, C.A. Jost, and B.G. Neel The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence Cell 68 1992 545 560
43. J. ten Hoeve, M. de Jesus Ibarra-Sanchez, Y. Fu, W. Zhu, M. Tremblay, and M. David Identification of a nuclear Stat1 protein tyrosine phosphatase Mol Cell Biol 22 2002 5662 5668
44. D. Schmidt, and S. Muller Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity Proc Natl Acad Sci USA 99 2002 2872 2877
45. K. Shuai, and B. Liu Regulation of gene-activation pathways by PIAS proteins in the immune system Nat Rev Immunol 5 2005 593 605
46. B. Liu, J. Liao, X. Rao, S.A. Kushner, C.D. Chung, and D.D. Change Inhibition of Stat1-mediated gene activation by PIAS1 Proc Natl Acad Sci USA 95 1998 10626 10631
47. C.D. Chung, J. Liao, B. Liu, X. Rao, P. Jay, and P. Perte Specific inhibition of Stat3 signal transduction by PIAS3 Science 278 1997 1803 1805
48. B. Liu, M. Gross, J. ten Hoeve, and K. Shuai A transcriptional corepressor of Stat1 with an essential LXXLL signature motif Proc Natl Acad Sci USA 98 2001 3203 3207
49. T. Aurora, B. Liu, H. He, J. Kim, T.L. Murphy, and K.M. Murphy PIASx is a transcriptional co-repressor of signal transducer and activator of transcription 4 J Biol Chem 278 2003 21327 21330
50. B. Liu, S. Mink, K.A. Wong, N. Stein, C. German, and P.W. Dempsey PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity Nat Immunol 5 2004 891 898
51. W. Roth, C. Dustman, M. Kieslinger, A. Gilmozzi, D. Irmer, and E. Kremmer PIASy-deficient mice display modest defects in IFN and Wnt signalling J Immunol 173 2004 6189 6199
52. Q. Zhang, P.N. Raghunath, L. Xue, M. Majewski, D.F. Carpentieri, and N. Odum Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma J Immunol 168 2002 466 474
53. M. Ueda, J. Ota, Y. Yamashita, Y.L. Choi, R. Ohki, and T. Wada DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome Br J Haematol 123 2003 288 296
54. A. Yoshimura, T. Ohkubo, T. Kiguchi, N.A. Jenkins, D.J. Gilbert, and N.G. Copeland A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors Embo J 14 1995 2816 2826
55. F. Verdier, S. Chretien, O. Muller, P. Varlet, A. Yoshimura, and S. Gisselbrecht Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation Possible involvement of the ubiquitinated Cis protein J Biol Chem 273 1998 28185 28190
56. R. Starr, T.A. Willson, E.M. Viney, L.J. Murray, J.R. Rayner, and B.J. Jenkins A family of cytokine-inducible inhibitors of signalling Nature 387 1997 917 921
57. T.A. Endo, M. Masuhara, M. Yokouchi, R. Suzuki, H. Sakamoto, and K. Mitsui A new protein containing an SH2 domain that inhibits JAK kinases Nature 387 1997 921 924
58. T. Naka, M. Narazaki, M. Hirata, T. Matsumoto, S. Minamoto, and A. Aono Structure and function of a new STAT-induced STAT inhibitor Nature 387 1997 924 929
59. J. Schmitz, M. Weissenbach, S. Haan, P.C. Heinrich, and F. Schaper SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130 J Biol Chem 275 2000 12848 12856
60. C.J. Greenhalgh, D. Metcalf, A.L. Thaus, J.E. Corbin, R. Uren, and P.O. Morgan Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling J Biol Chem 277 2002 40181 40184
61. B.T. Kile, B.A. Schulman, W.S. Alexander, N.A. Nicola, H.M. Martin, and D.J. Hilton The SOCS box: a tale of destruction and degradation Trends Biochem Sci 27 2002 235 241
62. P. De Sepulveda, K. Okkenhaug, J.L. Rose, R.G. Hawley, P. Dubreuil, and R. Rottapel Socs1 binds to multiple signalling proteins and suppresses steel factor-dependent proliferation Embo J 18 1999 904 915
63. D. Ungureanu, P. Saharinen, I. Junttila, D.J. Hilton, and O. Silvennoinen Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1 Mol Cell Biol 22 2002 3316 3326
64. S. Kamizono, T. Hanada, H. Yasukawa, S. Minoguchi, R. Kato, and M. Minoguchi The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2 J Biol Chem 276 2001 12530 12538
65. J. Frantsve, J. Schwaller, D.W. Sternberg, J. Kutok, and D.G. Gilliland Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation Mol Cell Biol 21 2001 3547 3557
66. L. Rui, M. Yuan, D. Frantz, S. Shoelson, and M.F. White SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2 J Biol Chem 277 2002 42394 42398
67. E. Liu, J.F. Cote, and K. Vuori Negative regulation of FAK signaling by SOCS proteins Embo J 22 2003 5036 5046
68. F. Verdier, R. Rabionet, F. Gouilleux, C. Beisenherz-Huss, P. Varlet, and O. Muller A sequence of the CIS gene promoter interacts preferentially with two associated STAT5A dimers: a distinct biochemical difference between STAT5A and STAT5B Mol Cell Biol 18 1998 5852 5860
69. H. Saito, Y. Morita, M. Fujimoto, M. Narazaki, T. Naka, and T. Kishimoto IFN regulatory factor-1-mediated transcriptional activation of mouse STAT-induced STAT inhibitor-1 gene promoter by IFN-gamma J Immunol 164 2000 5833 5843
70. D. Hebenstreit, P. Luft, A. Schmiedlechner, G. Regl, A.M. Frischauf, and F. Aberger IL-4 and IL-13 Induce SOCS-1 Gene Expression in A549 Cells by Three Functional STAT6-Binding Motifs Located Upstream of the Transcription Initiation Site J Immunol 171 2003 5901 5907
71. J. Travagli, M. Letourneur, J. Bertoglio, and J. Pierre STAT6 and Ets-1 form a stable complex that modulates SOCS-1 expression by IL-4 in keratinocytes J Biol Chem 279 2004 35182 35192
72. J.G. Zhang, A. Farley, S.E. Nicholson, T.A. Willson, L.M. Zugaro, and R.J. Simpson The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation Proc Natl Acad Sci USA 96 1996 2071 2076
73. B.Q. Vuong, T.L. Arenzana, B.M. Showalter, J. Losman, X.P. Chen, and J. Mostecki SOCS-1 localizes to the microtubule organizing complex-associated 20S proteasome Mol Cell Biol 24 2004 9092 9101
74. X.P. Chen, J.A. Losman, S. Cowan, E. Donahue, S. Fay, and B.Q. Vuong Pim serine/threonine kinases regulate the stability of Socs-1 protein Proc Natl Acad Sci USA 99 2002 2175 2180
75. T. Kishimoto, and H. Kikutani Knocking the SOCS off a tumor suppressor Nat Genet 28 2001 4 5
76. R. Rottapel, S. Ilangumaran, C. Neale, J. La Rose, J.M. Ho, and M.H. Nguyen The tumor suppressor activity of SOCS-1 Oncogene 21 2002 4351 4362
77. A.G. Jegalian, and H. Wu Regulation of Socs gene expression by the proto-oncoprotein GFI-1B: two routes for STAT5 target gene induction by erythropoietin J Biol Chem 277 2002 2345 2352
78. H. Miyoshi, H. Fujie, Y. Shintani, T. Tsutsumi, S. Shinzawa, and M. Makuuchi Hepatitis C virus core protein exerts an inhibitory effect on suppressor of cytokine signaling (SOCS)-1 gene expression J Hepatol 43 2005 757 763
79. H. Miyoshi, H. Fujie, K. Moriya, Y. Shintani, T. Tsutsumi, and M. Makuuchi Methylation status of suppressor of cytokine signaling-1 gene in hepatocellular carcinoma J Gastroenterol 39 2004 563 569
80. H. Yoshikawa, K. Matsubara, G.S. Qian, P. Jackson, J.D. Groopman, and J.E. Manning SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity Nat Genet 28 2001 29 35
81. O. Okochi, K. Hibi, M. Sakai, S. Inoue, S. Takeda, and T. Kaneko Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis Clin Cancer Res 9 2003 5295 5298
82. B. Li, J. Goyal, S. Dhar, G. Dimri, E. Evron, and S. Sukumar CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression Cancer Res 61 2001 8014 8021
83. N. Fukushima, N. Sato, F. Sahin, G.H. Su, R.H. Hruban, and M. Goggins Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms Br J Cancer 89 2003 338 343
84. H. Nagai, T. Naka, Y. Terada, T. Komazaki, A. Yabe, and E. Jin Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas J Hum Genet 48 2003 65 69
85. S. Fujitake, K. Hibi, O. Okochi, Y. Kodera, K. Ito, and S. Akiyama Aberrant methylation of SOCS-1 was observed in younger colorectal cancer patients J Gastroenterol 39 2004 120 124
86. S.Y. Lin, K.T. Yeh, W.T. Chen, H.C. Chen, S.T. Chen, and H.Y. Chiou Promoter CpG methylation of tumor suppressor genes in colorectal cancer and its relationship to clinical features Oncol Rep 11 2004 341 348
87. Y. Oshimo, K. Kuraoka, H. Nakayama, Y. Kitadai, K. Yoshida, and K. Chayama Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma Int J Cancer 112 2004 1003 1009
88. K.D. Sutherland, G.J. Lindeman, D.Y. Choong, S. Wittlin, L. Brentzell, and W. Phillips Differential hypermethylation of SOCS genes in ovarian and breast carcinomas Oncogene 23 2004 7726 7733
89. K.F. To, M.W. Chan, W.K. Leung, E.K. Ng, J. Yu, and A.H. Bai Constitutional activation of IL-6-mediated JAK/STAT pathway through hypermethylation of SOCS-1 in human gastric cancer cell line Br J Cancer 91 2004 1335 1341
90. C.Y. Chen, W. Tsay, J.L. Tang, H.L. Shen, S.W. Lin, and S.Y. Huang SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia Genes Chromosomes Cancer 37 2003 300 305
91. O. Galm, H. Yoshikawa, M. Esteller, R. Osieka, and J.G. Herman SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma Blood 101 2003 2784 2788
92. T.C. Liu, S.F. Lin, J.G. Chang, M.Y. Yang, S.Y. Hung, and C.S. Chang Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia Br J Haematol 123 2003 654 661
93. E. Uehara, S. Takeuchi, T. Tasaka, Y. Matsuhashi, Y. Yang, and M. Fujita Aberrant methylation in promoter-associated CpG islands of multiple genes in therapy-related leukemia Int J Oncol 23 2003 693 696
94. C.G. Ekmekci, M.I. Gutierrez, A.K. Siraj, U. Ozbek, and K. Bhatia Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia Am J Hematol 77 2004 233 240
95. H. Luo, P. Rose, D. Barber, W.P. Hanratty, S. Lee, and T.M. Roberts Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways Mol Cell Biol 17 1997 1562 1571
96. D. Watanabe, S. Ezoe, M. Fujimoto, A. Kimura, Y. Saito, and H. Nagai Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines Br J Haematol 126 2004 726 735
97. K. Brakensiek, F. Langer, B. Schlegelberger, H. Kreipe, and U. Lehmann Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome Br J Haematol 130 2005 209 217
98. Y. Niwa, H. Kanda, Y. Shikauchi, A. Saiura, K. Matsubara, and T. Kitagawa Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma Oncogene 24 2005 6406 6417
99. A. Weber, U.R. Hengge, W. Bardenheuer, I. Tischoff, F. Sommerer, and A. Markwarth SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition Oncogene 24 2005 6699 6708
100. C. Guiter, I. Dusanter-Fourt, C. Copie-Bergman, M.L. Boulland, S. Le Gouvello, and P. Gaulard Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma Blood 104 2004 543 549
101. I. Melzner, A.J. Bucur, S. Bruderlein, K. Dorsch, C. Hasel, and T.F. Barth Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line Blood 105 2005 2535 2542
102. I. Melzner, M.A. Weniger, A.J. Bucur, S. Bruderlein, K. Dorsch, and C. Hasel Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein Int J Cancer 2005
103. V. Lacronique, A. Boureux, R. Monni, S. Dumon, M. Mauchauffe, and P. Mayeux Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells Blood 95 2000 2076 2083